Morgan Stanley Protara Therapeutics, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$2.76 - $3.91 $161,015 - $228,105	58,339 Added 233356.0%	58,364 $182,000
Q4 2022 Feb 14, 2023	SELL	$2.43 - $3.7 $532 - $810	-219 Reduced 89.75%	25 $0
Q3 2022 Nov 14, 2022	SELL	$2.96 - $4.27 $6,541 - $9,436	-2,210 Reduced 90.06%	244 $1,000
Q2 2022 Oct 27, 2022	SELL	$2.8 - $5.33 $11,485 - $21,863	-4,102 Reduced 62.57%	2,454 $7,000
Q2 2022 Aug 15, 2022	SELL	$2.8 - $5.33 $11,485 - $21,863	-4,102 Reduced 62.57%	2,454 $7,000
Q1 2022 Oct 27, 2022	BUY	$4.19 - $6.9 $17,187 - $28,303	4,102 Added 167.16%	6,556 $33,000
Q1 2022 May 13, 2022	SELL	$4.19 - $6.9 $89,431 - $147,273	-21,344 Reduced 76.5%	6,556 $33,000
Q4 2021 Feb 14, 2022	BUY	$6.15 - $7.76 $8,105 - $10,227	1,318 Added 4.96%	27,900 $188,000
Q3 2021 Nov 15, 2021	BUY	$6.38 - $9.3 $169,593 - $247,212	26,582 New	26,582 $184,000

10.7M

1.8K

Ticker TARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,267,400
Market Cap $51M
Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.